Abstract Details

Title Early-Onset Parkinson’s Disease in Women: A comparison of Hormonal Exposure with Late-Onset Parkinson’s Disease and Unaffected Controls

Topic Movement Disorders

Presentation(s) N3 - Neuroscience in the Clinic: Menopause: Why Does It Matter for Neurologic Disease? (4:10 PM-4:20 PM)

Poster/Presentation
Number 001

Background Parkinson's disease (PD) is almost twice as common in men as compared to women. Although this difference seems at least partially explained by hormonal factors, there is a paucity of studies evaluating the role of hormonal exposure in women with EOPD.

Objective To compare the demographic characteristics and exposure to endogenous, exogenous estrogens and progestins between patients with Early-Onset Parkinson’s Disease (EOPD), Late-Onset Parkinson’s Disease (LOPD), and EOPD-matched unaffected controls.

Design/Methods We identified all female patients with EOPD in an incident cohort study from 1991 to 2010. All patients with motor symptoms onset before 50 years of age were defined as EOPD, while LOPD patients had a motor symptom onset after 50 years of age. Each EOPD patient was matched to an unaffected control. Their medical records were reviewed to determine demographic characteristics, medical, reproductive, and menopausal history.

Results A total of 318 women with EOPD and 170 women with LOPD were identified. Of these, 87 EOPD patients, 91 controls, and 84 LOPD patients had sufficient data on hormonal exposure in their medical records to be included in this study. There were no significant differences in race, ethnicity, or BMI between the three groups. EOPD patients were significantly more likely to have used hormonal contraception compared to controls and LOPD patients (p<0.001). The number of pelvic surgeries and the use of perimenopausal hormonal therapy preceding the onset of motor symptoms (both p<0.001) was significantly higher in LOPD compared to EOPD.

Conclusions Our study reports that there are no significant differences in hormonal exposure between controls and EOPD patients, except for exposure to hormonal contraception. The differences in the history of hormonal contraception, oophorectomy and perimenopausal treatment between EOPD and LOPD are probably linked to the age gap between the two cohorts.

Authors/Disclosures
Gaia Patane, MD PRESENTER	Dr. Patane has nothing to disclose.
Aidan Mullan (Mayo Clinic)	Aidan Mullan has nothing to disclose.
Capucine Piat, MD	Dr. Piat has nothing to disclose.
Pierpaolo Turcano, MD (Rush University Medical Center)	Dr. Turcano has nothing to disclose.
Rodolfo Savica, MD, PhD, FAAN (Mayo Clinic)	The institution of Dr. Savica has received research support from ACADIA Pharmaceuticals, Inc.

��ɫ��

��ɫ��